as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹2,608.5
Change
-37.6 (-1.42%)
Open
₹2,655.8
Prev. Close
₹2,646.1
Day High
₹2,666.7
Day Low
₹2,608.5
Volume Analysis
Traded
392,816
Delivered
192,198
Delivery %
48.93%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (23.6%)
- •Strong operating margin (21.0%)
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •Strong 3-year EPS growth (66.1%)
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹2,705.5 | ₹2,686.1 | ₹2,647.3 | ₹2,627.9 | ₹2,589.1 | ₹2,569.7 | ₹2,530.9 |
| Fibonacci | ₹2,686.1 | ₹2,663.87 | ₹2,650.13 | ₹2,627.9 | ₹2,605.67 | ₹2,591.93 | ₹2,569.7 |
| Camarilla | ₹2,624.51 | ₹2,619.17 | ₹2,613.84 | ₹2,627.9 | ₹2,603.17 | ₹2,597.83 | ₹2,592.5 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+28.74%
1 Week
-1.93%
1 Month
+18.89%
3 Months
+12.54%
6 Months
+15.47%
1 Year
+38.9%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹656.57
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
13.73%
Net margin 9.1% × asset turnover 0.79x × equity multiplier 1.91x
Company Overview
Sector
Healthcare
Market Cap
₹73,937 Cr
P/E (TTM)
36.5
ROE
23.6%
Book Value
₹397.0
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.
TopFund Analysis
Glenmark Pharmaceuticals holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 71/100. The strongest factor is Financial Strength (100/100), while Valuation (20/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (23.6%); strong operating margin (21.0%). FII holding has been falling.
TopFund Score — Fundamentals Quality
71/100 — GoodData confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company has delivered good profit growth of 19.4% CAGR over last 5 years
- −The company has delivered a poor sales growth of 9.19% over past five years.
- −Company has a low return on equity of -3.28% over last 3 years.
- −Debtor days have increased from 85.2 to 107 days.
- −Working capital days have increased from 41.2 days to 80.5 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Glenmark USA launched authorized generic axitinib tablets, 1 mg and 5 mg, on November 16, 2026.
Glenmark to hold investor meetings in Taiwan, Singapore and Switzerland from 16-11-2026 to 23-11-2026.
Glenmark schedules investor meetings in Taiwan, Singapore, and Switzerland on 16-18 Nov and 23 Nov 2026.
Glenmark schedules investor meetings in Taiwan, Singapore and Switzerland during 16-11-2026 to 23-11-2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,207 | 2,507 | 3,063 | 3,244 | 3,434 | 3,388 | 3,256 | 3,264 | 6,047 | 3,901 | 3,771 | 4,018 | 4,247 |
| Expenses + | 2,745 | 2,715 | 2,559 | 2,656 | 2,832 | 2,787 | 2,695 | 2,684 | 3,687 | 3,031 | 3,008 | 3,214 | 3,384 |
| Operating Profit | 462 | -209 | 504 | 588 | 602 | 600 | 561 | 581 | 2,360 | 870 | 763 | 805 | 864 |
| OPM % | 14.0% | -8.0% | 16.0% | 18.0% | 18.0% | 18.0% | 17.0% | 18.0% | 39.0% | 22.0% | 20.0% | 20.0% | 20.0% |
| Other Income + | -205 | 87 | 351 | 31 | 39 | 31 | -361 | -297 | -1,184 | -140 | -184 | 66 | -281 |
| Interest | 121 | 134 | 149 | 40 | 48 | 52 | 67 | 58 | 66 | 41 | 43 | 54 | 64 |
| Depreciation | 141 | 147 | 151 | 118 | 120 | 123 | 125 | 130 | 141 | 154 | 148 | 173 | 180 |
| Profit before tax | -6 | -403 | 555 | 462 | 473 | 456 | 8 | 96 | 967 | 534 | 388 | 643 | 338 |
| Tax % | 997.0% | -18.0% | 319.0% | 26.0% | 25.0% | 24.0% | 45.0% | 51.0% | 37.0% | 24.0% | 22.0% | 25.0% | 22.0% |
| Net Profit + | -62 | -331 | -1,214 | 340 | 354 | 348 | 4 | 47 | 610 | 403 | 301 | 483 | 264 |
| EPS in Rs | -3 | -12 | -43 | 12 | 13 | 12 | 0 | 2 | 22 | 14 | 11 | 17 | 9 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 6 | -19 | 2 | 7 | 7 | 35 | 6 | 1 | 76 | 15 | 16 | 23 | -30 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 6,563 | 7,562 | 9,079 | 9,074 | 9,865 | 10,641 | 10,944 | 12,305 | 11,583 | 11,813 | 13,322 | 16,983 | 15,937 |
| Expenses + | 5,348 | 6,125 | 7,043 | 7,457 | 8,280 | 8,942 | 8,860 | 9,978 | 9,948 | 10,618 | 10,970 | 12,410 | 12,636 |
| Operating Profit | 1,214 | 1,437 | 2,037 | 1,617 | 1,586 | 1,699 | 2,084 | 2,327 | 1,635 | 1,195 | 2,351 | 4,572 | 3,301 |
| OPM % | 18.0% | 19.0% | 22.0% | 18.0% | 16.0% | 16.0% | 19.0% | 19.0% | 14.0% | 10.0% | 18.0% | 27.0% | 21.0% |
| Other Income + | -180 | 20 | -44 | 89 | 375 | 191 | 95 | -101 | -10 | 336 | -259 | -1,805 | -540 |
| Interest | 190 | 179 | 237 | 286 | 335 | 377 | 353 | 298 | 349 | 516 | 207 | 209 | 202 |
| Depreciation | 300 | 234 | 264 | 302 | 326 | 417 | 444 | 487 | 569 | 582 | 486 | 573 | 656 |
| Profit before tax | 544 | 1,044 | 1,491 | 1,119 | 1,301 | 1,096 | 1,382 | 1,441 | 707 | 434 | 1,399 | 1,985 | 1,903 |
| Tax % | 61.0% | 29.0% | 26.0% | 28.0% | 29.0% | 29.0% | 30.0% | 31.0% | 47.0% | 430.0% | 25.0% | 31.0% | — |
| Net Profit + | 209 | 743 | 1,109 | 804 | 925 | 776 | 970 | 994 | 377 | -1,434 | 1,047 | 1,362 | 1,451 |
| EPS in Rs | 8 | 26 | 39 | 28 | 33 | 28 | 34 | 33 | 11 | -53 | 37 | 48 | 51 |
| Dividend Payout % | 26.0% | 8.0% | 5.0% | 7.0% | 6.0% | 9.0% | 7.0% | 7.0% | 24.0% | -5.0% | 7.0% | 10.0% | — |
| Sales growth | 9 | 15 | 20 | 0 | 9 | 8 | 3 | 12 | -6 | 2 | 13 | 27 | 0 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,756 | 3,601 | 4,464 | 5,135 | 5,577 | 6,042 | 7,036 | 9,058 | 9,446 | 7,820 | 8,821 | 10,484 | 11,184 |
| Borrowings + | 3,800 | 3,988 | 4,724 | 4,639 | 4,449 | 4,869 | 4,986 | 3,962 | 4,608 | 1,231 | 2,473 | 594 | 1,407 |
| Other Liabilities + | 2,726 | 2,575 | 2,548 | 2,793 | 3,235 | 3,729 | 3,524 | 4,003 | 5,289 | 5,279 | 4,669 | 8,801 | 8,780 |
| Total Liabilities | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 | 21,400 |
| Fixed Assets + | 2,015 | 2,594 | 2,755 | 3,030 | 3,670 | 5,029 | 5,129 | 5,887 | 5,422 | 4,210 | 4,487 | 5,915 | 6,385 |
| CWIP | 477 | 543 | 708 | 1,122 | 1,399 | 1,222 | 1,382 | 1,010 | 1,190 | 662 | 835 | 909 | 599 |
| Investments | 17 | 17 | 16 | 15 | 30 | 25 | 25 | 50 | 45 | 790 | 56 | 42 | 42 |
| Other Assets + | 5,799 | 7,039 | 8,285 | 8,429 | 8,190 | 8,393 | 9,040 | 10,105 | 12,715 | 8,697 | 10,613 | 13,041 | 14,373 |
| Total Assets | 8,309 | 10,193 | 11,764 | 12,595 | 13,289 | 14,668 | 15,575 | 17,052 | 19,371 | 14,358 | 15,991 | 19,907 | 21,400 |
| Equity Capital | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 482 | 345 | 657 | 1,648 | 1,324 | 1,392 | 1,131 | 1,109 | 625 | -265 | -828 | 3,445 |
| Cash from Investing Activity + | -712 | -950 | -1,001 | -1,003 | -883 | -774 | -662 | -316 | -515 | 4,387 | 58 | -1,237 |
| Cash from Financing Activity + | 199 | 699 | 543 | -468 | -739 | -445 | -442 | -520 | -77 | -3,906 | 787 | -2,709 |
| Net Cash Flow | -31 | 93 | 199 | 177 | -297 | 174 | 28 | 272 | 32 | 215 | 17 | -501 |
| Free Cash Flow | -56 | -544 | -76 | 625 | 712 | 616 | 456 | 320 | 75 | -1,162 | -1,576 | 2,090 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 66 | 57 | 67 | 124 | 111 | 109 | 79 | 72 | 77 | 65 | -6 | 92 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 18.7% | 18.58% | 18.42% | 17.06% | 15.96% | 15.56% | 15.05% | 13.97% | 14.02% | 13.7% | 13.81% | 14.17% |
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.64% | 46.64% | 46.65% | 46.65% | 46.65% | 46.65% |
| Government | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| FII | 23.71% | 21.38% | 20.98% | 23.05% | 23.51% | 23.15% | 20.62% | 20.73% | 19.2% | 20.35% | 20.89% | 21.51% |
| DII | 10.92% | 13.36% | 13.93% | 13.21% | 13.85% | 14.6% | 17.64% | 18.61% | 20.09% | 19.28% | 18.6% | 17.63% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Glenmark Pharmaceuticals (this stock) | 73,937 | 36.5 | 6.59 | 23.6% |
| Aster Dm Quality Care Ltd | 63,907 | 122.0 | 8.2 | 11.3% |
| Alkem Laboratories Ltd. | 61,875 | 28.6 | 4.16 | 18.9% |
| Fortis Healthcare Ltd | 61,047 | 56.9 | 5.81 | 11.2% |
| Biocon Limited. | 58,962 | 86.5 | 1.69 | 1.4% |
| Manipal Health Enterpri L | 89,630 | 95.6 | 5.36 | 12.7% |
| Lupin Limited | 89,994 | 16.0 | 3.75 | 28.7% |
Which Mutual Funds Hold Glenmark Pharmaceuticals?
Frequently Asked Questions about Glenmark Pharmaceuticals
Glenmark Pharmaceuticals (GLENMARK) closed at ₹2,608.5 on NSE on 19 November 2026, down 37.6 (1.42%) from the previous close.
Glenmark Pharmaceuticals trades on the NSE (National Stock Exchange of India) under the symbol GLENMARK.
Glenmark Pharmaceuticals has a trailing twelve-month P/E (price-to-earnings) ratio of 36.5.
Glenmark Pharmaceuticals has a dividend yield of 0.19%.
Glenmark Pharmaceuticals's 52-week high is ₹2,714.0 and its 52-week low is ₹1,818.0.
Glenmark Pharmaceuticals has a market capitalisation of ₹73,937 crore.
Glenmark Pharmaceuticals has a TopFund Quality Score of 71/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Glenmark Pharmaceuticals?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.